TNBCs are immunohistologically characterized by lack of estrogen receptor (ER) and progesterone receptor (PR) as well as human epidermal growth factor receptor 2 (HER2) amplification, and ~20% of all breast cancers are identified as TNBCs [1]. The gene discussed is ESR1; the disease is breast carcinoma.